Enlivex Ltd. announced positive 12-month results from its Phase I/IIa trial of Allocetra™ for moderate to severe knee osteoarthritis in patients aged 64 and older. The trial showed 79.2% of treated patients achieved meaningful pain reduction and improved knee function versus 47.6% in the placebo group, demonstrating a sustained benefit from a single treatment cycle. These results, consistent with earlier 3- and 6-month data, highlight Allocetra's potential as a durable therapy in a field lacking disease-modifying options. The data will be presented at the American College of Rheumatology Convergence in November 2026, with further Phase IIb trial results expected by mid-2027.
Enlivex's positive 12-month Phase I/IIa trial results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell. Among notable movers, RLAY traded at USD 18.75 with a 1-day gain of 2.18% and a typical hold time of 23 days, TWST was priced at USD 156.06 up 2.15%, and NTRA reached USD 423.00 with a 2.13% increase and a hold time of 18 days.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
